Safe Orthopaedics (ALSAF) | Financial Analysis & Statements
Safe Orthopaedics S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
11.0M
Total Liabilities
19.5M
Shareholders Equity
-8.4M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Safe Orthopaedics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5.0M | 5.8M | 5.9M | 4.6M | 3.7M |
| Cost of Goods Sold | 2.4M | 1.5M | 1.9M | 2.0M | 2.3M |
| Gross Profit | 2.6M | 4.3M | 3.9M | 2.6M | 1.4M |
| Gross Margin % | 52.6% | 74.4% | 67.0% | 56.6% | 38.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 213.0K | 262.0K | 307.0K | 66.0K | 38.0K |
| Other Operating Expenses | 8.8M | 1.6M | 2.1M | 2.4M | 2.0M |
| Total Operating Expenses | 9.0M | 1.9M | 2.4M | 2.5M | 2.1M |
| Operating Income | -10.6M | -6.3M | -6.0M | -7.6M | -6.7M |
| Operating Margin % | -209.8% | -108.8% | -102.2% | -166.2% | -181.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 2.1B | 218.0K | 424.0K | 638.0K | 861.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -2.1B | -271.3M | -7.0M | -6.7M | -8.3M |
| Income Tax | 65.2M | -65.9M | -1.0K | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -1.9B | -205.4M | -7.0M | -6.7M | -8.3M |
| Net Margin % | -38,272.6% | -3,536.0% | -118.8% | -147.1% | -225.5% |
| Key Metrics | |||||
| EBITDA | 66.0M | -266.7M | -5.6M | -5.2M | -6.9M |
| EPS (Basic) | €-249,977.07 | - | €-90.00 | €-1,341,800.00 | €-2,768,666.67 |
| EPS (Diluted) | €-249,977.07 | - | €-90.00 | €-99,999,999.99 | €-38,627,999.61 |
| Basic Shares Outstanding | 7718 | - | 72435 | 5 | 3 |
| Diluted Shares Outstanding | 7718 | - | 72435 | 5 | 3 |
Income Statement Trend
Safe Orthopaedics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 317.0K | 780.0K | 302.0K | 913.0K | 2.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 3.4M | 2.1M | 2.4M | 1.3M | 1.4M |
| Inventory | 3.4M | 4.3M | 4.5M | 3.6M | 2.9M |
| Other Current Assets | 1.0K | -1.0K | 161.0K | -1.0K | 2.0K |
| Total Current Assets | 7.0M | 8.5M | 9.3M | 8.2M | 8.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.5M | 3.6M | 5.3M | 7.7M | 6.5M |
| Goodwill | 148.0K | 10.0K | 3.8M | 4.0M | 4.1M |
| Intangible Assets | 148.0K | 10.0K | 187.0K | 23.0K | 39.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.0K | - | -96.0K | -1.0K | -1.0K |
| Total Non-Current Assets | 4.0M | 69.5M | 7.3M | 6.6M | 5.9M |
| Total Assets | 11.0M | 77.9M | 16.5M | 14.9M | 14.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.7M | 2.1M | 3.6M | 1.9M | 1.8M |
| Short-term Debt | 11.0M | 268.4M | 5.0M | 3.6M | 935.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 550.0K | 2.4M | 1.8M | 333.0K | 318.0K |
| Total Current Liabilities | 18.0M | 275.2M | 12.4M | 9.0M | 5.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 828.0K | 2.8M | 5.1M | 5.3M | 8.2M |
| Deferred Tax Liabilities | 247.0K | 39.0K | 148.0K | - | - |
| Other Non-Current Liabilities | 61.0K | 2.2M | 10.0K | 57.0K | 1.0K |
| Total Non-Current Liabilities | 1.5M | 5.0M | 5.3M | 5.4M | 8.3M |
| Total Liabilities | 19.5M | 280.3M | 17.8M | 14.5M | 14.1M |
| Equity | |||||
| Common Stock | 37.0K | 3.4M | 14.2M | 5.6M | 3.4M |
| Retained Earnings | -1.9B | -205.4M | -7.0M | -6.7M | -8.3M |
| Treasury Stock | - | - | 78.0K | 79.0K | 80.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -8.4M | -202.4M | -1.3M | 398.0K | 237.0K |
| Key Metrics | |||||
| Total Debt | 11.8M | 271.2M | 10.1M | 8.9M | 9.1M |
| Working Capital | -11.0M | -266.8M | -3.2M | -799.0K | 2.6M |
Balance Sheet Composition
Safe Orthopaedics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.9B | -205.4M | -7.0M | -6.7M | -8.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | 39.0K | - | - | - |
| Working Capital Changes | -1.2M | 68.0M | 182.0K | 0 | 945.0K |
| Operating Cash Flow | -69.8M | 126.3M | -6.4M | -5.6M | -6.6M |
| Investing Activities | |||||
| Capital Expenditures | -93.0K | -56.0K | -858.0K | -2.0M | -548.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 61.0K | - | 262.0K | 36.0K | 6.0K |
| Investing Cash Flow | -33.0K | -56.0K | -597.0K | -2.7M | -3.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 0 | 658.0K | 1.4M |
| Debt Repayment | -2.1B | -2.3M | -3.1M | -430.0K | -748.0K |
| Financing Cash Flow | 3.7M | 1.7M | 5.7M | 8.1M | 11.9M |
| Free Cash Flow | -3.4M | 64.7M | -6.3M | -8.2M | -6.5M |
| Net Change in Cash | -66.2M | 127.9M | -1.3M | -256.0K | 2.3M |
Cash Flow Trend
Safe Orthopaedics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.00
Forward P/E
-11.71
Price to Sales
0.03
PEG Ratio
-11.71
Profitability Ratios
Profit Margin
52.57%
Operating Margin
181.52%
Return on Equity
22,908.13%
Return on Assets
-3.44%
Financial Health
Current Ratio
0.39
Debt to Equity
-1.40
Beta
-0.92
Per Share Data
EPS (TTM)
€-9,792.48
Book Value per Share
€0.00
Revenue per Share
€0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALSAF | 148.6K | 0.00 | - | 22,908.13% | 52.57% | -1.40 |
| Sartorius Stedim | 15.8B | 59.45 | 3.86 | 6.59% | 8.98% | 63.11 |
| Crossject S.A | 105.6M | - | - | 212.74% | 0.00% | -4.61 |
| Visiomed Group SA | 52.8M | 59.67 | - | 3.64% | 45.95% | 0.32 |
| Spineway S.A | 5.8M | 16.20 | 0.25 | -9.46% | -17.47% | 6.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.